A 28-year-old woman with treatment-resistant dissociative PTSD showed dramatic improvement after 10 sessions of cannabis-assisted psychotherapy — drawing parallels to psychedelic-assisted therapy.
Read this if you're interested in the intersection of cannabis and psychotherapy, or if you have treatment-resistant PTSD and want to know about emerging therapeutic approaches beyond standard medication.
What the researchers found
Dissociative PTSD (D-PTSD) is a particularly severe form of PTSD where patients experience detachment from their own body and surroundings — depersonalization and derealization — on top of standard PTSD symptoms. Standard treatments often fail for this population, and targeted interventions are essentially nonexistent.
This case report describes a novel approach: cannabis-assisted psychotherapy (CAP). A 28-year-old woman with complex D-PTSD underwent 10 sessions over 5 months, each combining cannabis administration with a specific psychotherapy framework — psychedelic somatic interactional psychotherapy, an approach borrowed from the psychedelic therapy world.
The parallels to psychedelic therapy are intentional. At sufficient doses, cannabis can produce experiences similar to classic psychedelics: oceanic boundlessness (a sense of unity and expansiveness), ego dissolution, and emotional breakthrough. The therapists used these cannabis-induced states as a therapeutic window, much as psilocybin or MDMA therapists use the altered state to facilitate processing of traumatic memories.
The results were striking. From baseline to post-treatment, the patient showed large improvements across PTSD symptoms, dissociation, depression, anxiety, sleep quality, and overall functioning. The treatment also incorporated integrative cognitive behavioral therapy between cannabis sessions.
This is a single case report, not a clinical trial — it can't prove cannabis-assisted psychotherapy works for D-PTSD. But it introduces a conceptual framework for using cannabis therapeutically in psychotherapy that hasn't been formally described before, and the patient's response was clinically meaningful.
Why it matters
This case report sits at the intersection of two growing fields: medical cannabis and psychedelic-assisted therapy. While psychedelic therapy with psilocybin and MDMA has gained significant research momentum for PTSD, cannabis-assisted psychotherapy is virtually unexplored. If cannabis can facilitate similar therapeutic states at a fraction of the regulatory and logistical complexity of Schedule I psychedelics, it could open a more accessible pathway for treatment-resistant PTSD patients.
The numbers in context
1 patient, 28 years old, female. 10 sessions over 5 months (twice monthly). Treatment combined cannabis administration with psychedelic somatic interactional psychotherapy and integrative CBT. Large improvements reported across PTSD severity, dissociation, depression, anxiety, sleep, and functioning from baseline to post-treatment.
How the study worked
Case report of a single 28-year-old female patient with complex D-PTSD. Treatment: 10 sessions of cannabis-assisted psychotherapy (CAP) scheduled twice monthly over 5 months, using psychedelic somatic interactional psychotherapy combined with integrative cognitive behavioral therapy. Outcomes measured included PTSD symptoms, dissociation severity, depression, anxiety, sleep quality, and functioning.
Who was studied
1 female aged 28 with complex dissociative posttraumatic stress disorder (D-PTSD)
What this study cannot tell us
Single case report — the lowest level of clinical evidence. No control condition; improvements could reflect natural recovery, placebo effects, the psychotherapy itself (independent of cannabis), or the therapeutic relationship. The patient's demographics (young, female, engaged enough to commit to 10 sessions) limit generalizability. The psychedelic-like effects of cannabis are dose-dependent and unpredictable, raising safety concerns for broader application. No long-term follow-up reported.
How to read the evidence
Single case report — the most preliminary level of clinical evidence. While the patient's improvement is notable, a single uncontrolled case cannot establish treatment efficacy. This is best understood as a proof-of-concept introducing a new therapeutic model.
When this study was published
Published in 2023. Cannabis-assisted psychotherapy is a very new concept; clinical trials may not yet exist.
The bigger picture
This case report introduces cannabis-assisted psychotherapy as a distinct treatment concept, positioning it alongside the growing psychedelic therapy literature. For the RethinkTHC database, it connects to the broader mental health cluster — anxiety (RTHC-00009, RTHC-00077), sleep (RTHC-00083, RTHC-00095), and the endocannabinoid system's role in emotional regulation. The deliberate use of cannabis's psychedelic-like properties at higher doses is a fundamentally different therapeutic model from the low-dose symptom management that most medical cannabis research examines.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Could cannabis-assisted psychotherapy be tested in a controlled trial for D-PTSD? What cannabis dose and administration route optimally produces therapeutic psychedelic-like states without adverse effects? How does cannabis-assisted psychotherapy compare to psilocybin or MDMA-assisted therapy for PTSD? Is the cannabis essential, or would the psychotherapy framework alone produce similar results?
Read the original research
Cannabis-assisted psychotherapy for complex dissociative posttraumatic stress disorder: A case report.
Frontiers in psychiatry, 14, 1051542
Frontiers in Psychiatry is a reputable journal focusing on various aspects of mental health and psychiatric research.
Citation
Ragnhildstveit, Anya; Kaiyo, Miriam; Snyder, Matthew Brian; Jackson, Laura Kate; Lopez, Alex; Mayo, Chasity; Miranda, Alyssa Claire; August, River Jude; Seli, Paul; Robison, Reid; Averill, Lynnette Astrid. (2023). Cannabis-assisted psychotherapy for complex dissociative posttraumatic stress disorder: A case report.. Frontiers in psychiatry, 14, 1051542. https://doi.org/10.3389/fpsyt.2023.1051542
Explore the wider topic
- Weed Withdrawal Anxiety in Public: When Leaving the House Feels Impossible
- The DARE Response to Anxiety for Cannabis Withdrawal
- The Cannabis Withdrawal Anxiety Toolkit: Quick Techniques That Work
- Why Anxiety Gets Worse Before It Gets Better After Quitting Weed
- Breathing Exercises for Weed Withdrawal Anxiety
- Cannabis-Induced Anxiety: When Weed Stops Being Fun
- Does Weed Help or Hurt Anxiety? What Research Actually Shows
- Grounding Techniques for Cannabis Withdrawal: A Practical Toolkit
- Quitting Weed with Health Anxiety: Why Every Symptom Feels Like a Crisis
- How to Manage Anxiety Without Weed: 15 Evidence-Based Alternatives
- Quitting Weed with Anxiety Disorder: A Careful Approach
- Quitting Weed When You're on Anxiety Medication: What to Know
- Self-Medicating Anxiety with Weed: Why It Works Until It Doesn't
- Do I Need Therapy to Quit Weed? When Professional Help Makes Sense
- Weed and Anxiety: The Paradox That Traps People
- The Biphasic Effect: Low-Dose Calms, High-Dose Panics
- Weed and Generalized Anxiety Disorder (GAD): Why It Backfires
- Weed and Panic Attacks: The Connection Nobody Talks About
- Weed and Paranoia: When Cannabis Turns Your Mind Against You
- Weed and Social Anxiety: Why It Feels Like the Only Thing That Helps
- Why Weed Stopped Working for Your Anxiety
- Weed Withdrawal Anxiety: Understanding the Panic and How to Cope
- Weed Withdrawal Panic Attacks at Night: Why They Happen and How to Get Through Them
- Going Back to Work During Weed Withdrawal: Managing Anxiety and Staying Functional
- Withdrawal Anxiety vs Pre-Existing Anxiety: How to Tell the Difference